Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 210, Issue 3, Pages 563-579Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20120662
Keywords
-
Categories
Funding
- Swedish Cancer Society
- StratCan
- ERC
- Swedish Research Council [K2011-67X-21865-01-6]
- Swedish Childhood Cancer Society
- Jeansson's Foundation
- Magn Bergvalls Foundation
- Ake Wiberg's Foundation
- BioCARE
- Lund University
- BHF senior basic science research fellowship
- CRUK
- Dutch Cancer Society
- British Heart Foundation [RG/12/2/29416] Funding Source: researchfish
- Medical Research Council [MR/K011375/1] Funding Source: researchfish
- MRC [MR/K011375/1] Funding Source: UKRI
Ask authors/readers for more resources
Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses and cures in cancer patients. We investigated the long-term consequences of genetically impaired angiogenesis by engineering multiple tumor models deprived of endoglin, a co-receptor for TGF-beta in endothelial cells actively engaged in angiogenesis. Tumors from endoglin-deficient mice adapted to the weakened angiogenic response, and refractoriness to diminished endoglin signaling was accompanied by increased metastatic capability. Mechanistic studies in multiple mouse models of cancer revealed that deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of endothelial-to-mesenchymal transition, a process of previously unknown significance in cancer biology, but shown by us to be associated with a reduced capacity of the vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of multiple angiogenic pathways for the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available